Webinar: The New 340B ADR Final Rule Process: Overview and Implications for the Future

Douglas and his co-panelists will examine the Final Rule, which establishes an ADR process for disputes between 340B Drug Pricing Program covered entities and drug manufacturers required to sell outpatient drugs at reduced prices to the covered entities. The panel will evaluate the new ADR process and its application to claims that drug manufacturers are potentially overcharging 340B covered entities, the restrictions on the use of contract pharmacies by covered entities, and the manufacturers’ claims of duplicate discounts or diversion. Additionally, Douglas and his co-panelists will outline the path moving forward and how the Final Rule will influence future interactions between covered entities, drug manufacturers, and the Health Resources and Services Administration.